Why the study?
Does escalated intravenous esmolol alter myocardial mechanics measured by MRI 3D tagging in healthy volunteers?
Does escalated intravenous esmolol alter myocardial mechanics measured by MRI 3D tagging in healthy volunteers?
Low-dose esmolol paradoxically increases myocardial contraction in healthy volunteers, supporting the theory that selective low-dose beta-blockade may unload ventricular performance by blocking transversely intruding cardiomyocytes.
Should not alter practice; leaves open whether low-dose beta-blockade unloads ventricles in patients.
Beta-blockers contribute to treatment of heart failure. Their mechanism of action, however, is incompletely understood. Gradients in beta-blocker sensitivity of helically aligned cardiomyocytes compared with counteracting transversely intruding cardiomyocytes seem crucial. We hypothesize that selective blockade of transversely intruding cardiomyocytes by low-dose beta-blockade unloads ventricular performance. Cardiac magnetic resonance imaging (MRI) 3D tagging delivers parameters of myocardial performance. We studied 13 healthy volunteers by MRI 3D tagging during escalated intravenous administration of esmolol. The circumferential, longitudinal, and radial myocardial shortening was determined for each dose. The curves were analyzed for peak value, time-to-peak, upslope, and area-under-the-curve. At low doses, from 5 to 25 μg·kg(-1)·min(-1), peak contraction increased while time-to-peak decreased yielding a steeper upslope. Combining the values revealed a left shift of the curves at low doses compared with baseline without esmolol. At doses of 50 to 150 μg·kg(-1)·min(-1), a right shift with flattening occurred. In healthy volunteers we found more pronounced myocardial shortening at low compared with clinical dosage of beta-blockers. In patients with ventricular hypertrophy and higher prevalence of transversely intruding cardiomyocytes selective low-dose beta-blockade could be even more effective. MRI 3D tagging could help to determine optimal individual beta-blocker dosing avoiding undesirable side effects.
No takes yet. Share an insight, caveat, or question.
Schmitt et al. (2015) studied Healthy volunteers (n=13). Esmolol vs. Baseline without esmolol was evaluated on Circumferential, longitudinal, and radial myocardial shortening (peak value, time-to-peak, upslope, and area-under-the-curve).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: